82results about "Chemokines" patented technology

The invention relates generally to compositions and methods for purifying the desired species from a mixture of desired heterodimer and contaminating homodimer immunoglobulin variants by modifying the isoelectric point(s) of the individual chains.

Provided herein are modified NK-92 cells comprising a nucleic acid encoding C-C chemokine receptor type 7 (CCR7) operably linked to a promoter. Optionally, the cells further comprise a nucleic acid encoding C-C motif ligand 21 (CCL21), a nucleic acid encoding C-C motif ligand 19 (CCL19) or a combination thereof. Also provided are compositions and kits comprising the modified NK-92 cells. Provided are methods of making the modified cells and methods of treating cancer using the cells.

The disclosure relates to the technical field of vaccine preparation, and in particular to an immune-enhancing delivery system formed by targeted antigen delivery by CCL11. The system further enhances immunogenicity by fusing a chemokine CCL11 with a corresponding antigen molecule, and adding a T2 label at a terminal of the antigen molecule. The system can be a nucleic acid vector or a fusion protein or the like to be applied to prevention and / or treatment of diseases caused by a corresponding antigen. According to the present invention, by utilizing a chemotactic binding capacity of CCL11 with a surface receptor of an immune cell such as a DC, different antigen proteins are transported to the surface of the DC, so that the efficiency of phagocytosis, processing and presentation of the DC on various antigen proteins is improved, and the effect of preventing and treating related diseases is improved.

The present disclosure generally relates to a viral vector carrying a synthetic cancer antigen and a chemokine. Also provided herein are compositions and uses of the viral vector for delivering, such as tagging, a tumor with the synthetic cancer antigen.

Provided herein are macromolecules that conditionally induce a cellular effector function (e.g., a biological or therapeutic activity) based on the presence of a disease signature ligand, compositions comprising the same, and methods of using the same.

This disclosure provides, inter alia, genetically engineered cells having an artificial protospacer-adjacent motif (PAM) introduced via a CRISPR / Cas-mediated gene editing, and optionally, one or more modifications in a target gene. The disclosure also provides methods and compositions, including gRNAs, that can be used to make such modifications.

The present invention relates to novel peptides, compositions and kits comprising said peptides, for use as active ingredients for preventing or treating pain in a subject in need thereof. In vitro or ex vivo methods for modulating the expression of these peptides are also described herein.

The present disclosure relates to CXCR3 ligands having CXCR3-expressing-cell migration-inducing activity, and specifically to amino acid modifications and amino acid sequences that are important for CXCR3-expressing-cell migration-inducing activity.

The present invention relates to immune cells expressing IL-7 (interleukin-7), CCL19 (CC Motif Chemokine Ligand 19), or a combination thereof, and compositions containing the same as active ingredients for the prevention or treatment of cancer or infectious diseases. The present invention provides a multifaceted and synergistic therapeutic effect through the complementary immune response between the patient's endogenous T cells and the infused natural killer cells by injecting only a therapeutically effective amount of immune cells other than T cells. Furthermore, the present invention also provides a significantly improved therapeutic effect when administering T cells and immune cells other than T cells, specifically natural killer cells, by allowing these different cell groups to act more intensively at the lesion site.

The present invention relates to the technical field of vaccine preparation, and in particular to an immune-enhancing delivery system formed by targeted antigen delivery by CCL11. The system further enhances immunogenicity by fusing a chemokine CCL11 with a corresponding antigen molecule, and adding a T2 label at a terminal of the antigen molecule. The system can be a nucleic acid vector or a fusion protein or the like to be applied to prevention and / or treatment of diseases caused by a corresponding antigen. According to the present invention, by utilizing a chemotactic binding capacity of CCL11 with a surface receptor of an immune cell such as a DC, different antigen proteins are transported to the surface of the DC, so that the efficiency of phagocytosis, processing and presentation of the DC on various antigen proteins is improved, and the effect of preventing and treating related diseases is improved. The key point of the present invention is that a T2 sequence added to an antigen can enhance an immune response.

The invention relates to methods of treating a tumor in a subject by administering to the subject the following active agents: (a) interleukin- 12 (IL-12), a nucleotide expressing IL-12, or combinations thereof; and (b) c-c motif chemokine ligand 3 (CCL3), a nucleotide expressing CCL3, or combinations thereof. The invention also relates to therapeutic compositions that include the following active agents; (a) IL-12, a nucleotide expressing IL-12, or combinations thereof; and (b) CCL3, a nucleotide expressing CCL3, or combinations thereof.

To provide cleavable activators of CXCR3 and methods of use.SOLUTION: Disclosed is a recombinant C-X-C motif chemokine ligand (CXCL) peptide modified to introduce a cleavage site for a protease (e.g., a protease that is activated during an inflammation response). The CXCL peptide has an ability to activate CXCR3 until the protease cleaves the peptide. The proteolytic cleavage of the CXCL peptide minimizes pro-inflammatory response and inhibits the development of fibrosis. The CXCL may be CXCL10, CXCL4, CXCL9 or CXCL11.SELECTED DRAWING: None

The present disclosure provides immunomodulatory fusion proteins-metal hydroxide complexes comprising an immunomodulatory domain adsorbed to a metal hydroxide via ligand exchange. The disclosure also features compositions and methods of using the same, for example, to treat cancer.

The present invention discloses a CXCL-BPI fusion protein that can be used for treating Gram-negative bacterial infections, a coding nucleic acid thereof, a method for expressing and preparing the same, and a use thereof in the manufacture of a pharmaceutical composition for treating Gram-negative bacterial infections. The CXCL-BPI fusion protein comprises a human ELR+CXC chemokine and a bioactive fragment of N-terminal domain of human BPI, and has the dual functions of both ELR+CXC chemokine and BPI, with ability of binding to LPS and directly killing Gram-negative bacteria, and also inducing chemotaxis and promoting phagocytes to target, bind to and phagocytize Gram-negative bacteria. The mechanism of action of the fusion protein can overcome Gram-negative bacterial drug resistance.

To provide a vaccinia virus having a therapeutic gene introduced therein as a foreign gene, and a therapeutic composition including the vaccinia virus.SOLUTION: A vaccinia virus contains, as a foreign gene, at least one immunoregulatory gene.SELECTED DRAWING: None

The present invention relates to a fusion protein comprising at least two cytokines, of which at least one is a modified cytokine with a strongly reduced binding affinity to its receptor, or to one of its receptors. Preferably, both cytokines are connected by a linker, preferably a GGS linker. The invention relates further to said fusion protein for use in treatment of diseases.

Described herein are compositions and methods for regulating the expression of effector molecules using engineered CCL3 promoters.Also described are immunoresponsive cells comprising the same.Furthermore, wherein the engineered CCL3 promoter comprises a truncation of at least one nucleotide motif, wherein the truncation increases the inducibility of the engineered CCL3 promoter in the presence of an immune cell activation signal compared to the inducibility of the wild-type CCL3 promoter in the presence of the same immune cell activation signal.

Disclosed herein are programmable bacteria for tumor-targeted immunotherapeutic delivery. In certain embodiments, the programmable bacteria comprise at least one synchronized lysis circuit contained in a single operon which are capable of being further engineered to cyclically produce anti-cancer therapeutic agents including but not limited to nanobodies against immune checkpoint inhibitors and over-expressed markers in cancers, toxins, tumor antigens, cytokines, and chemokines. In some embodiments, the programmable bacteria comprise at least one synchronized lysis circuit contained in a single operon and at least one plasmid producing a therapeutic agent, i.e., at least one plasmid comprising a nucleic acid sequence which encodes a therapeutic agent. The disclosure also provides methods of curing and treating cancer using the programmable bacteria.

Described is a polypeptide including the intracellular domain of CX3CL1 (CX3CL1-ICD), including an amino acid sequence that is at least 90% identical to SEQ ID NO: 1 and pharmaceutical compositions including the above-described polypeptide and a pharmaceutically acceptable excipient. Also included are nucleic acids expressing the polypeptides and expression cassettes and vectors comprising the nucleic acids. The polypeptides can be used in methods of treating a subject exhibiting a symptom of a neurodegenerative disease and / or diagnosed with a neurodegenerative disease and methods of treating a subject exhibiting a symptom of diabetes and / or diagnosed with diabetes comprising administering to the subject the pharmaceutical composition described herein.

To provide cleavable activators of CXCR3 and methods of use.SOLUTION: Disclosed is a recombinant C-X-C motif chemokine ligand (CXCL) peptide modified to introduce a cleavage site for a protease (e.g., a protease that is activated during an inflammation response). The CXCL peptide has an ability to activate CXCR3 until the protease cleaves the peptide. The proteolytic cleavage of the CXCL peptide minimizes pro-inflammatory response and inhibits the development of fibrosis. The CXCL may be CXCL10, CXCL4, CXCL9 or CXCL11.SELECTED DRAWING: None

The application discloses a CXCL-BPI fusion protein which can be used for treating gram-negative bacterial infection, a coding nucleic acid of the CXCL-BPI fusion protein, an expression preparation method, and application of the CXCL-BPI fusion protein to preparation of a pharmaceutical composition for treating gram-negative bacterial infection. The CXCL-BPI fusion protein comprises a human ELR+CXC chemokine and a human BPI N-terminal domain functional fragment, has the functions of combining LPS, directly killing gram-negative bacteria and chemotactic cell migration, and also has the functions of promoting phagocytes to be guided to combine and phagocytize gram-negative bacteria, and the action mechanism can overcome gram-negative bacterial drug resistance.

This disclosure relates to antigen-encoding RNAs and other polynucleotides that can be used in vaccine compositions. In some examples, RNA also encodes chemoattractants such as chemerin, CXC-motif chemokine ligand 9 (CXCL9), CXC-motif chemokine ligand 10 (CXCL10), or CXC-motif chemokine ligand 11 (CXCL11). This disclosure also relates to the use of RNAs and compositions in methods for inducing an immune response in a subject.

The present disclosure relates to RNAs and other polynucleotides encoding an antigen, which can be used in vaccine compositions. In some examples, the RNA also encodes a chemoattractant, such as chemerin, C-X-C motif chemokine ligand 9 (CXCL9), C-X-C motif chemokine ligand 10 (CXCL10) or C-X-C motif chemokine ligand 11 (CXCL11). The present disclosure also relates to use of the RNAs and compositions in methods of inducing an immune response in a subject.

Disclosed herein are hypoimmunogenic stem cell-derived β cells for use in various applications, such as cell therapy.

The present invention relates to an agent for inhibiting the expression or activity of G protein-coupled receptor 182 (GPR182) protein for use in the treatment or prevention of a pathological condition selected from myocardial infarction, myocardial ischemia, myocardial necrosis, cardiac hypertrophy, cardiac fibrosis, limb ischemia, ischemia-related tissue degeneration, stroke, and cancer, wherein (a) the agent for inhibiting the expression of GPR182 protein is selected from siRNA, miRNA, shRNA, ribozyme, and antisense nucleic acid molecules; and / or (b) the agent for inhibiting the activity of GPR182 protein specifically binds to the GPR182 protein and inhibits the binding of one or more endogenous ligands to the GPR182 protein, and the agent is selected from an antibody, Fc fusion polypeptide, adnectin, affibody, affilin, anticalin, atrimer, avimer, evibody, Kunitz-type domain, designed ankyrin repeat protein (DARPin), finomer, peptide or peptidomimetic, aptamer, and small molecule; or any combination thereof and / or a hetero- or homo-oligomeric covalent or non-covalent complex.

The specification relates to a method of manufacturing a diabetic foot patient-specific skin regeneration sheet, and a diabetic foot patient-specific skin regeneration sheet. The method includes extracting autologous adipose tissue, removing fibers in the autologous adipose tissue, crushing the autologous adipose tissue, and acquiring an adipose tissue extract by filtrating the crushed autologous adipose tissue.

Methods for treating or inhibiting fibrosis in a subject by administering specific chemokine cocktails are described. The chemokine cocktails include combinations of CXCL4, CXCL9, CXCL10, CXCL11 and / or CXCL12 proteins, or the combination of CXCL1 and CXCL8 proteins. Methods for increasing extracellular matrix (ECM) production and / or treating a wound in a subject by administering specific chemokine cocktails are also described. In these methods, the cocktails include CXCL1 and CXCL8 proteins and optionally further include a CCL2 protein.

The present invention relates to methods and compositions comprising a delivery vehicle for delivery of tissue trafficking modulators to modulate the trafficking of immune cell to a specific locus. The invention also relates to methods for treating or preventing a disease and disorder, including cancer, an infectious disease and an immunological disorder.

A method of modifying a cell, the method comprising: transfecting a cell to be modified with a transfection composition to cause the cell to comprise and / or express a foreign gene, the transfection composition containing a foreign nucleic acid molecule comprising the foreign gene, at least a portion of the foreign nucleic acid molecule being obtained from a host cell; and, in the portion of the foreign nucleic acid molecule obtained from the host cell, the content of genomic DNA of the host cell is about 10% (w / w) or less.